Knowing that most don't follow here but I will still post some thoughts
Just found that over 19m was spent for FDA approval possibly in the last few years.
But the crucial thing is in the last report 2.8m was spent and maybe 1.2m the year before
If you strip out the FDA expenses, Cyclopharm still isn't breakeven - perhaps 3m loss last FY and the same previous year.
This is the likely reason why there is still nervousness even after FDA approval
In addition, they still need to spend money for the US market launch even though they have 8.2m of inventory for that market. So there is about 20m allocated for the US market launch. In other words, I don't think CYC will be profitable until FY25 (hoping I'm wrong though). There was also the presso with the CR mentioned by accident that was retracted the same day last week!
Should have done more research before on why they are not breaking even with so many countries ex-US on board.
Hope CYC can become cashflow positive after US launch.
So despite the FDA news, this is more a wait and watch until we can see something meaningful in the financials.
Having said that, Bell potter increased the price target to 4.25. But looking at their track records, especially with CXL I don't think BP can be trusted
[held]